ID,PFS_Paper,Final_judge_PFS,ORR_Paper,Final_judge_ORR,Blinding_Central,Trial_phase,Trial_number,Trial_name,Tumor,Funding,Industry_name,Trial_arm,Treatment_line,Drug_name_intervention,Drug_classification_intervention,Drug_name_control,Drug_classification_control,Primary_outcome,Response_criteria,Randomized_patient_number_intervention,Randomized_patient_number_control,Follow_up_period_months_median,PFS_INV_HR,PFS_INV_95%CI_lower,PFS_INV_95%CI_upper,PFS_CNT_HR,PFS_CNT_95%CI_lower,PFS_CNT_95%CI_upper,ORR_N_INV_intervention,CR+PR_INV_intervention,ORR_N_INV_control,CR+PR_INV_control,ORR_N_CNT_intervention,CR+PR_CNT_intervention,ORR_N_CNT_control,CR+PR_CNT_control,Median_OS_intervention,Median_OS_control,OS_HR,OS_95%CI_lower,OS_95%CI_upper,title,journal,year,authors,url,pubmed_id,Reason_PFS,Reason_ORR
9,Investigator,Investigator,Investigator + Central,Investigator,Unclear,Phase 2,NCT02268695,GORTEC 2014-01 TPExtreme,Head and Neck Cancer,Industry,Merck Santé and Chugai Pharma.,2,1,"docetaxel, platinum, cetuximab",Target therapy and chemotherapy,"platinum, fluorouracil, cetuximab",Target therapy and chemotherapy,OS,RECIST 1.1,271,270,34.4/30.2,0.88,0.74,1.04,NA,NA,NA,269,155,270,154,NA,NA,NA,NA,14.5,13.4,0.89,0.74,1.08,"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.",The Lancet. Oncology,2021,Guigay J and Aupﾃｩrin A and Fayette J and Saada-Bouzid E and Lafond C and Taberna M and Geoffrois L and Martin L and Capitain O and Cupissol D and Castanie H and Vansteene D and Schafhausen P and Johnson A and Even C and Sire C and Duplomb S and Evrard C and Delord JP and Laguerre B and Zanetta S and Chevassus-Clﾃｩment C and Fraslin A and Louat F and Sinigaglia L and Keilholz U and Bourhis J and Mesia R,https://pubmed.ncbi.nlm.nih.gov/33684370/,33684370,No central,No central
26,Investigator + Central,Investigator + Central (INV data not shown),Central,Central,Blinding,Phase 3,NCT03215706,CheckMate 9LA,Non-small cell lung cancer,Industry,Bristol Myers Squibb,2,1,nivolumab plus ipilimumab with chemotherapy,Immune checkpoint inhibitor and chemotherapy,Chemotherapy,Chemotherapy,OS,RECIST 1.1,361,358,13.2,NA,NA,NA,0.68,0.57,0.82,NA,NA,NA,NA,361,138,358,89,15.6,10.9,0.66,0.55,0.8,"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.",The Lancet. Oncology,2021,Paz-Ares L and Ciuleanu TE and Cobo M and Schenker M and Zurawski B and Menezes J and Richardet E and Bennouna J and Felip E and Juan-Vidal O and Alexandru A and Sakai H and Lingua A and Salman P and Souquet PJ and De Marchi P and Martin C and Pﾃｩrol M and Scherpereel A and Lu S and John T and Carbone DP and Meadows-Shropshire S and Agrawal S and Oukessou A and Yan J and Reck M,https://pubmed.ncbi.nlm.nih.gov/33476593/,33476593,No local,No local
82,Investigator + Central,Central,Unclear,Central?,Blinding,Phase 3,NCT01808573,NALA,Breast cancer,Industry,Puma Biotechnology,2,≥3,Neratinib plus capecitabine,Target therapy and chemotherapy,Lapatinib plus capecitabine,Target therapy and chemotherapy,PFS,RECIST 1.1,307,314,29.9,NA,NA,NA,0.76,0.63,0.93,NA,NA,NA,NA,256,84,270,72,24,22.2,0.88,0.72,1.07,Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 竕･ 2 HER2-Directed Regimens: Phase III NALA Trial.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2020,Saura C and Oliveira M and Feng YH and Dai MS and Chen SW and Hurvitz SA and Kim SB and Moy B and Delaloge S and Gradishar W and Masuda N and Palacova M and Trudeau ME and Mattson J and Yap YS and Hou MF and De Laurentiis M and Yeh YM and Chang HT and Yau T and Wildiers H and Haley B and Fagnani D and Lu YS and Crown J and Lin J and Takahashi M and Takano T and Yamaguchi M and Fujii T and Yao B and Bebchuk J and Keyvanjah K and Bryce R and Brufsky A,https://pubmed.ncbi.nlm.nih.gov/32678716/,32678716,No local,No local
100,Investigator + Central,Central,Central,Central,Blinding,Phase 3,NCT03091192,SAVIOR,Renal cell cancer,Industry,AstraZeneca,2,≥ 1,Savolitinib,Target therapy,Sunitinib,Target therapy,PFS,RECIST 1.1,33,27,NA,NA,NA,NA,0.71,0.37,1.36,NA,NA,NA,NA,33,9,27,2,Not reached,13.2,0.51,0.21,1.17,Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.,JAMA oncology,2020,Choueiri TK and Heng DYC and Lee JL and Cancel M and Verheijen RB and Mellemgaard A and Ottesen LH and Frigault MM and L'Hernault A and Szijgyarto Z and Signoretti S and Albiges L,https://pubmed.ncbi.nlm.nih.gov/32469384/,32469384,No local,No local
133,Investigator + Central,Central,Investigator + Central,Central,Unclear,Phase 3,NCT02339116,TRIBE2,Colorectal cancer,Industry,"The GONO Cooperative Group, the ARCO Foundation, and F Hoffmann–La Roche.",2,1,FOLFOXIRI plus bevacizumab and reintroduction after progression,Target therapy and chemotherapy,mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab,Target therapy and chemotherapy,PFS,RECIST 1.1,339,340,35.9,NA,NA,NA,0.74,0.63,0.88,NA,NA,NA,NA,339,210,340,171,27.4,22.5,0.82,0.68,0.98,"Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.",The Lancet. Oncology,2020,Cremolini C and Antoniotti C and Rossini D and Lonardi S and Loupakis F and Pietrantonio F and Bordonaro R and Latiano TP and Tamburini E and Santini D and Passardi A and Marmorino F and Grande R and Aprile G and Zaniboni A and Murgioni S and Granetto C and Buonadonna A and Moretto R and Corallo S and Cordio S and Antonuzzo L and Tomasello G and Masi G and Ronzoni M and Di Donato S and Carlomagno C and Clavarezza M and Ritorto G and Mambrini A and Roselli M and Cupini S and Mammoliti S and Fenocchio E and Corgna E and Zagonel V and Fontanini G and Ugolini C and Boni L and Falcone A,https://pubmed.ncbi.nlm.nih.gov/32164906/,32164906,No local,No local
155,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 3,NCT02511405,GLOBE,Glioblastoma,Industry,VBL Therapeutics,2,"2, 3",VB-111pllus bevacizumab,Immune therapy plus Target therapy,bevacizumab,Target therapy,OS,Response Assessment in Neuro-Oncology (RANO),128,128,NA,NA,NA,NA,1.345,1.03,1.755,NA,NA,NA,NA,128,35,128,28,6.8,7.9,1.204,0.91,1.592,A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).,Neuro-oncology,2020,Cloughesy TF and Brenner A and de Groot JF and Butowski NA and Zach L and Campian JL and Ellingson BM and Freedman LS and Cohen YC and Lowenton-Spier N and Rachmilewitz Minei T and Fain Shmueli S and Wen PY,https://pubmed.ncbi.nlm.nih.gov/31844890/,31844890,No local,No local
167,Investigator + Central,Central,Investigator + Central,Central,Unclear,Phase 2b,NCT02195180,No name,Pancretic cancer,Industry,ERYtech Pharma,2,2,Eryaspase plus chemotherapy,Chemotherapy,Chemotherapy,Chemotherapy,OS and PFS,RECIST 1.1,95,46,6.1/4.7,NA,NA,NA,0.56,0.37,0.84,NA,NA,NA,NA,95,12,46,3,6,4.4,0.6,0.41,0.87,"Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.","European journal of cancer (Oxford, England : 1990)",2020,Hammel P and Fabienne P and Mineur L and Metges JP and Andre T and De La Fouchardiere C and Louvet C and El Hajbi F and Faroux R and Guimbaud R and Tougeron D and Bouche O and Lecomte T and Rebischung C and Tournigand C and Cros J and Kay R and Hamm A and Gupta A and Bachet JB and El Hariry I,https://pubmed.ncbi.nlm.nih.gov/31760314/,31760314,No local,No local
172,Investigator + Central,No PFS,No ORR,No ORR,Unclear,Phase 2,NCT02125357,No name,Prostate cancer,Industry and Public,"Canadian Cancer Society Research Institute, Prostate Cancer Canada, Movember Foundation, Prostate
Cancer Foundation, Terry Fox New Frontiers Program, BC Cancer Foundation, Jane and Aatos Erkko Foundation,
Janssen, and Astellas.",2,2,Abiraterone acetate plus prednisone→Enzaltamide,Hormone therapy,Enzaltamide→Abiraterone acetate plus prednisone,Hormone therapy,"time to second PSA progression
and PSA response (≥30% decline from baseline) on second-line therapy,",,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,,,,,"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.",The Lancet. Oncology,2019,Khalaf DJ and Annala M and Taavitsainen S and Finch DL and Oja C and Vergidis J and Zulfiqar M and Sunderland K and Azad AA and Kollmannsberger CK and Eigl BJ and Noonan K and Wadhwa D and Attwell A and Keith B and Ellard SL and Le L and Gleave ME and Wyatt AW and Chi KN,https://pubmed.ncbi.nlm.nih.gov/31727538/,31727538,No PFS,No ORR
235,Investigator + Central,Central,Investigator,Investigator?,Blinding,Phase 3,NCT02588261,No name,Non-small cell lung cancer,Industry,"Astellas Pharma, Inc",2,1,Naquotinib (ASP8273),Target therapy,erlotinib or gefitinib,Target therapy,PFS,RECIST 1.1,267,263,3.5/3.6,NA,NA,NA,1.611,1.086,2.391,267,88,263,126,NA,NA,NA,NA,NA,NA,NA,NA,NA,"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.",Annals of oncology : official journal of the European Society for Medical Oncology,2019,Kelly RJ and Shepherd FA and Krivoshik A and Jie F and Horn L,https://pubmed.ncbi.nlm.nih.gov/31070709/,31070709,No local,No central
283,No PFS,No PFS,Investigator + Central,NO ORR,Blinding,Phase 3,NCT02142738,KEYNOTE-024,Non-small cell lung cancer,Industry,Merck Sharp & Dohme LLC,2,1,pembrolizumab,Immune checkpoint inhibitor,Chemotherapy,Chemotherapy,PFS,RECIST 1.1,154,151,25.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,30,14.2,0.63,0.47,0.86,Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2019,Reck M and Rodrﾃｭguez-Abreu D and Robinson AG and Hui R and Csﾅ壮zi T and Fﾃｼlﾃｶp A and Gottfried M and Peled N and Tafreshi A and Cuffe S and O'Brien M and Rao S and Hotta K and Vandormael K and Riccio A and Yang J and Pietanza MC and Brahmer JR,https://pubmed.ncbi.nlm.nih.gov/30620668/,30620668,No PFS,No ORR
317,Investigator + Central,Central,Central,Central,Blinding,Phase 3,NCT02395172,JAVELIN Lung 200,Non-small cell lung cancer,Industry,Merck and Pfizer,2,≥2,Avelumab,Immune checkpoint inhibitor,Docetaxel,Chemotherapy,OS,RECIST 1.1,396,396,18.3,NA,NA,NA,1.16,0.97,1.4,NA,NA,NA,NA,396,59,396,44,10.5,9.9,0.9,0.75,1.08,"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.",The Lancet. Oncology,2018,Barlesi F and Vansteenkiste J and Spigel D and Ishii H and Garassino M and de Marinis F and ﾃ奔gﾃｼroﾄ殕u M and Szczesna A and Polychronis A and Uslu R and Krzakowski M and Lee JS and Calabrﾃｲ L and Arﾃｩn Frontera O and Ellers-Lenz B and Bajars M and Ruisi M and Park K,https://pubmed.ncbi.nlm.nih.gov/30262187/,30262187,No local,No local
326,Investigator + Central,Central,Investigator + Central,Central,Unclear,Phase 1/2,NCT02400788,No name,Hepatocellular cancer,Industry,"Yakult Honsha Co., LTD",2,1,resminostat + sorafenib,Chemotherapy,sorafenib,Chemotherapy,TTP,RECIST 1.1,86,84,NA,NA,NA,NA,0.984,0.684,1.414,NA,NA,NA,NA,83,3,84,8,11.8,14.1,1.046,0.704,1.555,"Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.",Investigational new drugs,2018,Tak WY and Ryoo BY and Lim HY and Kim DY and Okusaka T and Ikeda M and Hidaka H and Yeon JE and Mizukoshi E and Morimoto M and Lee MA and Yasui K and Kawaguchi Y and Heo J and Morita S and Kim TY and Furuse J and Katayama K and Aramaki T and Hara R and Kimura T and Nakamura O and Kudo M,https://pubmed.ncbi.nlm.nih.gov/30198057/,30198057,No local,No local
332,Investigator + Central,"Central, No HR",Investigator + Central,Central,Unclear,Phase 2,NCT01164189,TAVAREC,Glioma,Industry,Roche Pharmaceuticals,2,2,temozolomide plus bevacizumab,Target therapy and chemotherapy,temozolomide,Chemotherapy,OS,RANO criteria,78,77,28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,69,36,72,32,13.8,15,1.11,0.77,1.6,"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.",The Lancet. Oncology,2018,van den Bent MJ and Klein M and Smits M and Reijneveld JC and French PJ and Clement P and de Vos FYF and Wick A and Mulholland PJ and Taphoorn MJB and Lewis J and Weller M and Chinot OL and Kros JM and de Heer I and Verschuere T and Coens C and Golfinopoulos V and Gorlia T and Idbaih A,https://pubmed.ncbi.nlm.nih.gov/30115593/,30115593,No PFS,No local
379,Investigator + Central,Central,Central,Central,Unclear,Phase 2,NCT01004003,No name,Hepatocellular cancer,Industry,Boehringer Ingelheim,2,1,Nintedanib,Target therapy,sorafenib,Target therapy,TTP,RECIST 1.0,62,31,NA,NA,NA,NA,1.35,0.78,2.34,NA,NA,NA,NA,62,1,31,2,11.9,11.4,0.88,0.52,1.47,"A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.",British journal of cancer,2018,Palmer DH and Ma YT and Peck-Radosavljevic M and Ross P and Graham J and Fartoux L and Deptala A and Studeny M and Schnell D and Hocke J and Loembﾃｩ AB and Meyer T,https://pubmed.ncbi.nlm.nih.gov/29563636/,29563636,No local,No local
388,Investigator + Central,Central,Investigator + Central,Central,Unclear,Phase 2,NCT01395758,No name,Non-small cell lung cancer,Industry,ArQule and Daichii Sanyko,2,≥2,tivantinib plus erlotinib,Target therapy,"pemetrexed, docetaxel, or gemcitabine",Chemotherapy,PFS,RECIST 1.1,51,45,3.4,data not shown,,,1.19,0.71,1.97,data not shown,,,,51,0,45,4,6.8,8.5,1.2,0.76,1.88,Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.,"Lung cancer (Amsterdam, Netherlands)",2018,Gerber DE and Socinski MA and Neal JW and Wakelee HA and Shirai K and Sequist LV and Rosovsky RP and Lilenbaum RC and Bastos BR and Huang C and Johnson ML and Hesketh PJ and Subramaniam DS and Dietrich MF and Chai F and Wang Y and Kazakin J and Schwartz B and Schiller JH and Brahmer JR and Kelly RJ,https://pubmed.ncbi.nlm.nih.gov/29496255/,29496255,No local,No local
395,Investigator + Central,Investigator,Investigator + Central,Investigator,Unclear,Phase 2,NCT02295930,MACBETH,Colorectal cancer,Public,"the Italian cooperative Gruppo Oncologico Nord Ovest, the ARCO Foundation, and Merck Serono SpA in Italy",2,1,"mFOLFOXIRI plus cetuximab followed by cetuximab
plus cetuximab followed by cetuximab (arm A) or bevacizumab",Target therapy and chemotherapy,mFOLFOXIRI plus cetuximab followed by bevacizumab,Target therapy and chemotherapy,PFS,RECIST 1.1,74,69,44,0.83,0.57,1.21,NA,NA,NA,59,40,57,43,NA,NA,NA,NA,33.2,32.2,0.92,0.57,1.47,Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.,JAMA oncology,2018,Cremolini C and Antoniotti C and Lonardi S and Aprile G and Bergamo F and Masi G and Grande R and Tonini G and Mescoli C and Cardellino GG and Coltelli L and Salvatore L and Corsi DC and Lupi C and Gemma D and Ronzoni M and Dell'Aquila E and Marmorino F and Di Fabio F and Mancini ML and Marcucci L and Fontanini G and Zagonel V and Boni L and Falcone A,https://pubmed.ncbi.nlm.nih.gov/29450468/,29450468,No central,No central
505,Investigator + Central,Central?,Investigator + Central,Central?,Unclear,Phase 3,NCT01207011,No name,Non-small cell lung cancer,Industry,"Sumitomo Dainippon Pharma Co., Ltd.",2,"2, 3",amrubicin,Chemotherapy,docetaxel,Chemotherapy,PFS,RECIST 1.1,101,101,NA,NA,NA,NA,0.9,0.65,1.25,NA,NA,NA,NA,97,14,97,19,14.6,13.5,0.97,0.69,1.36,"A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.",Annals of oncology : official journal of the European Society for Medical Oncology,2017,Yoshioka H and Katakami N and Okamoto H and Iwamoto Y and Seto T and Takahashi T and Sunaga N and Kudoh S and Chikamori K and Harada M and Tanaka H and Saito H and Saka H and Takeda K and Nogami N and Masuda N and Harada T and Kitagawa H and Horio H and Yamanaka T and Fukuoka M and Yamamoto N and Nakagawa K,https://pubmed.ncbi.nlm.nih.gov/28426104/,28426104,No local,No local
542,Investigator + Central,Central,Investigator + Central,Central,Unclear,Phase 1/2,JapicCTI-132123,No name,Non-small cell lung cancer,Industry,Yakult Honsha.,2,≥2,Resminostat plus Docetaxel ,Chemotherapy,Docetaxel,Chemotherapy,PFS,RECIST 1.1,54,54,NA,Data not shown,,,1.354,0.835,2.195,NA,NA,NA,NA,54,4,53,8,15.3,15.7,1.493,0.881,2.531,"Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.",Investigational new drugs,2017,Tambo Y and Hosomi Y and Sakai H and Nogami N and Atagi S and Sasaki Y and Kato T and Takahashi T and Seto T and Maemondo M and Nokihara H and Koyama R and Nakagawa K and Kawaguchi T and Okamura Y and Nakamura O and Nishio M and Tamura T,https://pubmed.ncbi.nlm.nih.gov/28138828/,28138828,No local,No local
628,Investigator + Central,Central?,Investigator + Central,Central?,Blinding,Phase 2,NCT00851084,AFFIRM,Colorectal cancer,Industry,"Sanofi and Regeneron Pharmaceuticals, Inc.",2,1,Aflibercept and mFOLFOX6,Target therapy and chemotherapy,mFOLFOX6,chemotherapy,PFS,RECIST 1.0,119,117,17.5,NA,NA,NA,1,0.74,1.36,NA,NA,NA,NA,,49.10%,,45.90%,19.5,22.3,0.98,0.66,1.45,Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.,Annals of oncology : official journal of the European Society for Medical Oncology,2016,Folprecht G and Pericay C and Saunders MP and Thomas A and Lopez Lopez R and Roh JK and Chistyakov V and Hﾃｶhler T and Kim JS and Hofheinz RD and Ackland SP and Swinson D and Kopp M and Udovitsa D and Hall M and Iveson T and Vogel A and Zalcberg JR,https://pubmed.ncbi.nlm.nih.gov/27091810/,27091810,No local,No ORR
629,No PFS,TTP,Investigator + Central,Investigator,Unclear,Phase 2,NCT01232296,No name,Hepatocellular cancer,Industry,Novartis Pharmaceuticals,2,1,Dovitinib,Target therapy,Sorafenib,Target therapy,OS,RECIST 1.1,82,83,26.2,NA,NA,NA,NA,NA,NA,82,5,83,9,NA,NA,NA,NA,34.6,36.7,1.27,0.9,1.79,"Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.","Hepatology (Baltimore, Md.)",2016,Cheng AL and Thongprasert S and Lim HY and Sukeepaisarnjaroen W and Yang TS and Wu CC and Chao Y and Chan SL and Kudo M and Ikeda M and Kang YK and Pan H and Numata K and Han G and Balsara B and Zhang Y and Rodriguez AM and Zhang Y and Wang Y and Poon RT,https://pubmed.ncbi.nlm.nih.gov/27082062/,27082062,No PFS,No central
653,Investigator + Central,Investigator,Investigator + Central,Investigator,Blinding,Phase 2,NCT01005199,SAKK 77/08 and SASL 29,Hepatocellular cancer,Industry and Public,"Novartis Pharma Switzerland and Hungary and by Bayer (Schweiz) AG and Education, Research and Innovation (SERI)",2,1,sorafenib plus everolimus,Target therapy,sorafenib,Target therapy,PFS,RECIST 1.1,60,46,20,0.9,0.6,1.4,No HR,No HR,No HR,NA,NA,NA,NA,59,6,46,0,12,10,No HR,No HR,No HR,"Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).",Annals of oncology : official journal of the European Society for Medical Oncology,2016,Koeberle D and Dufour JF and Demeter G and Li Q and Ribi K and Samaras P and Saletti P and Roth AD and Horber D and Buehlmann M and Wagner AD and Montemurro M and Lakatos G and Feilchenfeldt J and Peck-Radosavljevic M and Rauch D and Tschanz B and Bodoky G,https://pubmed.ncbi.nlm.nih.gov/26884590/,26884590,No central,No local
660,Investigator + Central,No PFS (No HR),Investigator + Central,No ORR,Unclear,Phase 2,No registry,No name,Non-small cell lung cancer,Public,"research grants from the Central Hospital of Zibo, China.",2,"2, 3",Pemetrexed and cyclophosphamide,Chemotherapy,Pemetrexed,Chemotherapy,PFS,RECIST 1.1,30,32,30.6,No HR,No HR,No HR,No HR,No HR,No HR,NA,NA,NA,NA,NA,NA,NA,NA,9.1,9.1,NA,NA,NA,Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer.,International journal of clinical and experimental pathology,2015,Li D and He S,https://pubmed.ncbi.nlm.nih.gov/26823793/,26823793,No PFS,No ORR
671,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 2/3,NCT01905657,KEYNOTE-010,Non-small cell lung cancer,Industry,Merck & Co.,3,≥2,Pembrolizumab 10 mg/kg,Immune checkpoint inhibitor,Docetaxel,Chemotherapy,OS and PFS,RECIST 1.1,346,343,13.1,NA,NA,NA,0.79,0.66,0.94,NA,NA,NA,NA,346,64,343,32,12.7,8.5,0.61,0.49,0.75,"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","Lancet (London, England)",2016,Herbst RS and Baas P and Kim DW and Felip E and Pﾃｩrez-Gracia JL and Han JY and Molina J and Kim JH and Arvis CD and Ahn MJ and Majem M and Fidler MJ and de Castro G Jr and Garrido M and Lubiniecki GM and Shentu Y and Im E and Dolled-Filhart M and Garon EB,https://pubmed.ncbi.nlm.nih.gov/26712084/,26712084,No local,No local
717,No PFS,TTP,Investigator + Central,Central?,Blinding,Phase 2,NCT00570882,RESTORE,Renal cell cancer,Public,Korea Healthcare Technology R&D Project,2,1,Sunitinib two weeks on and one weeks off,Target therapy,Sunitinib four weeks on and two weeks off ,Target therapy,FFS,RECIST 1.0,38,36,30,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,38,18,36,12,30.5,28.4,1.15,0.64,2.04,RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.,Annals of oncology : official journal of the European Society for Medical Oncology,2015,Lee JL and Kim MK and Park I and Ahn JH and Lee DH and Ryoo HM and Song C and Hong B and Hong JH and Ahn H,https://pubmed.ncbi.nlm.nih.gov/26347107/,26347107,No PFS,No local
731,Investigator + Central,Central?,Investigator + Central,Central?,Unclear,Phase 2,NCT01500720,ARD12166,Small-cell lung cancer,Industry,Sanofi,2,1,Cabazitaxel,Chemotherapy,Topotecan,Chemotherapy,PFS,RECIST 1.1,90,89,NA,NA,NA,NA,2.17,1.563,3.01,NA,NA,NA,NA,73,0,79,8,5.2,6.8,1.57,1.1,2.25,Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,2015,Evans TL and Cho BC and Udud K and Fischer JR and Shepherd FA and Martinez P and Ramlau R and Syrigos KN and Shen L and Chadjaa M and Wolf M,https://pubmed.ncbi.nlm.nih.gov/26200278/,26200278,No local,No local
758,No PFS,No PFS,Investigator + Central,Investigator,Unclear,Phase 2,NCT01033240,No name,Hepatocellular cancer,Industry,Daiichi Sankyo Pharma Development,3,1,"tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib",Target therapy,sorafenib,Target therapy,TTP,RECIST 1.1,55,55,NA,NA,NA,NA,NA,NA,NA,55,8,55,6,Data not shown,,,,12.2,8.2,NA,NA,NA,Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.,Journal of hepatology,2015,Cheng AL and Kang YK and He AR and Lim HY and Ryoo BY and Hung CH and Sheen IS and Izumi N and Austin T and Wang Q and Greenberg J and Shiratori S and Beckman RA and Kudo M,https://pubmed.ncbi.nlm.nih.gov/26071796/,26071796,No PFS,No central
769,Investigator,Investigator? TTF,Investigator + Central,Central,Blinding,Phase 3,NCT00769704,No name,Melanoma,Industry,Amgen,2,≥2,Talimogene laherparepvec (T-VEC),Immune therapy,granulocyte macrophage colony-stimulating factor (GM-CSF),Immune therapy,durable response rate (DRR),modified WHO criteria,295,141,44.4,0.42,0.32,0.54,NA,NA,NA,NA,NA,NA,NA,295,78,141,8,23.3,18.9,0.79,0.62,1,Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2015,Andtbacka RH and Kaufman HL and Collichio F and Amatruda T and Senzer N and Chesney J and Delman KA and Spitler LE and Puzanov I and Agarwala SS and Milhem M and Cranmer L and Curti B and Lewis K and Ross M and Guthrie T and Linette GP and Daniels GA and Harrington K and Middleton MR and Miller WH Jr and Zager JS and Ye Y and Yao B and Li A and Doleman S and VanderWalde A and Gansert J and Coffin RS,https://pubmed.ncbi.nlm.nih.gov/26014293/,26014293,No central,No local
800,Investigator + Central,Cental,Investigator + Central,Cental,Blinding,Phase 3,NCT01721746,CheckMate 037,Melanoma,Industry,Bristol-Myers Squibb.,2,≥2,Nivolumab,Immune checkpoint inhibitor,chemotherapy,chemotherapy,OS and ORR,RECIST 1.1,272,133,8.4,NA,NA,NA,"0.82; 99·99% CI 0.32–2.05,",,,NA,NA,NA,NA,120,38,47,5,NR,NR,NR,NR,NR,"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.",The Lancet. Oncology,2015,Weber JS and D'Angelo SP and Minor D and Hodi FS and Gutzmer R and Neyns B and Hoeller C and Khushalani NI and Miller WH Jr and Lao CD and Linette GP and Thomas L and Lorigan P and Grossmann KF and Hassel JC and Maio M and Sznol M and Ascierto PA and Mohr P and Chmielowski B and Bryce A and Svane IM and Grob JJ and Krackhardt AM and Horak C and Lambert A and Yang AS and Larkin J,https://pubmed.ncbi.nlm.nih.gov/25795410/,25795410,No local,No local
839,Investigator + Central,Central,Investigator + Central,Investigator,No blinding,Phase 3,NCT00720512,BEBYP,Colorectal cancer,Public,Italian Gruppo Oncologico Nord-Ovest cooperative group and the ARCO onlus foundation and Italian Drug Regulatory Agency,2,2,Bevacizumab and chemotherapy,Target therapy and Chemotherapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.0,92,92,45.3,0.7,0.52,0.95,NA,NA,NA,92,21,92,17,NA,NA,NA,NA,14.1,15.5,0.77,0.56,1.06,Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.,Annals of oncology : official journal of the European Society for Medical Oncology,2015,Masi G and Salvatore L and Boni L and Loupakis F and Cremolini C and Fornaro L and Schirripa M and Cupini S and Barbara C and Safina V and Granetto C and Fea E and Antonuzzo L and Boni C and Allegrini G and Chiara S and Amoroso D and Bonetti A and Falcone A,https://pubmed.ncbi.nlm.nih.gov/25600568/,25600568,No central,No central
861,Investigator + Central,Central?,Investigator + Central,Central?,Unclear,Phase 2,NCT00418743,GFPC 0501,Small-cell lung cancer,Industry,"AMGEN France, Baxter, UCB",2,2,"Oral Chemotherapy (Lomustine,Cyclophosphamide, Etoposide)
",Chemotherapy,"Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine)",Chemotherapy,OS,RECIST 1.1,65,66,NA,NA,NA,NA,1.03,NA,NA,NA,NA,NA,NA,65,19,66,18,6.1,5.8,0.94,NA,NA,"Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.",Clinical lung cancer,2015,Gervais R and Le Caer H and Monnet I and Falchero L and Baize N and Olivero G and Thomas P and Berard H and Auliac JB and Chouaid C,https://pubmed.ncbi.nlm.nih.gov/25467927/,25467927,No PFS,No local
873,Investigator + Central,Central? No HR,Investigator + Central,Central?,Unclear,Phase 2,NCT01107444,No name,Non-small cell lung cancer,Industry,Eli Lilly,2,2,LY2181308 and Docetaxel,Chemotherapy,Docetaxel,Chemotherapy,change in tumor size,RECIST 1.1,120,60,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,114,7,48,1,7.9,8.8,P=0.481,,,Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,2014,Natale R and Blackhall F and Kowalski D and Ramlau R and Bepler G and Grossi F and Lerchenmﾃｼller C and Pinder-Schenck M and Mezger J and Danson S and Gadgeel SM and Summers Y and Callies S and Andrﾃｩ V and Das M and Lahn M and Talbot D,https://pubmed.ncbi.nlm.nih.gov/25436803/,25436803,No PFS,No local
909,Investigator + Central,"Central, No HR",Investigator + Central,Central,Unclear,Phase 2,No registry,No name,Glioblastoma,Industry,Boehringer Ingelheim,3,2,afatinib,Target therapy,temozolomide,Chemotherapy,PFS,RANO criteria,41,39,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,41,1,39,4,9.8,10.6,NA,NA,NA,"Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.",Neuro-oncology,2015,Reardon DA and Nabors LB and Mason WP and Perry JR and Shapiro W and Kavan P and Mathieu D and Phuphanich S and Cseh A and Fu Y and Cong J and Wind S and Eisenstat DD,https://pubmed.ncbi.nlm.nih.gov/25140039/,25140039,No PFS,No local
911,Investigator + Central,Central,No ORR,No ORR,Blinding,Phase 2,No registry,No name,Gastrointestinal stromal tumours,Industry,AB Science,2,2,Masitinib,Target therapy,Sunitinib,Target therapy,PFS,RECIST 1.0? 1.1?,23,21,14,NA,NA,NA,1.1,0.6,2.2,NA,NA,NA,NA,NA,NA,NA,NA,NR,15.2,0.27,0.09,0.85,Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.,Annals of oncology : official journal of the European Society for Medical Oncology,2014,Adenis A and Blay JY and Bui-Nguyen B and Bouchﾃｩ O and Bertucci F and Isambert N and Bompas E and Chaigneau L and Domont J and Ray-Coquard I and Blﾃｩsius A and Van Tine BA and Bulusu VR and Dubreuil P and Mansfield CD and Acin Y and Moussy A and Hermine O and Le Cesne A,https://pubmed.ncbi.nlm.nih.gov/25122671/,25122671,No local,No ORR
996,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 3,NCT00294996,STM01-102,Breast cancer,Industry,Sopherion Therapeutics,2,1,nonpegylated liposomal doxorubicin + trastuzumab + paclitaxel,Target therapy and Chemotherapy,trastuzumab + paclitaxel,Target therapy and Chemotherapy,PFS,RECIST 1.0,181,182,31,NA,NA,NA,0.837,0.648,1.082,NA,NA,NA,NA,181,121,182,113,33.6,29,0.793,0.61,1.031,Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,2014,Baselga J and Manikhas A and Cortﾃｩs J and Llombart A and Roman L and Semiglazov VF and Byakhov M and Lokanatha D and Forenza S and Goldfarb RH and Matera J and Azarnia N and Hudis CA and Rozencweig M,https://pubmed.ncbi.nlm.nih.gov/24401928/,24401928,No local,No local
1004,Investigator + Central,Investigator,Investigator + Central,Investigator,Unclear,Phase 2,NCT00456833,No name,Non-small cell lung cancer,Industry,Novartis Pharmaceuticals,2,≥2,Everolimus and erlotinib,Target therapy,erlotinib,Target therapy,DCR,RECIST 1.0,66,67,NA,0.769,0.506,1.167,Data not shown,,,66,8,67,7,Data not shown,,,,9.1,9.7,1.279,0.69,2.371,Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,2014,Besse B and Leighl N and Bennouna J and Papadimitrakopoulou VA and Blais N and Traynor AM and Soria JC and Gogov S and Miller N and Jehl V and Johnson BE,https://pubmed.ncbi.nlm.nih.gov/24368400/,24368400,No central,No central
1006,Investigator + Central,Central?,Investigator + Central,Central?,Unclear,Phase 3,NCT00287768,START,Gastric cancer,Industry,Sanofi,2,1,docetaxel and S‐1,Chemotherapy,S‐1,Chemotherapy,OS,RECIST 1.0,316,323,11.4,NA,NA,NA,0.77,0.65,0.9,NA,NA,NA,NA,237,92,243,65,12.5,10.8,0.84,0.71,0.99,Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).,Journal of cancer research and clinical oncology,2014,Koizumi W and Kim YH and Fujii M and Kim HK and Imamura H and Lee KH and Hara T and Chung HC and Satoh T and Cho JY and Hosaka H and Tsuji A and Takagane A and Inokuchi M and Tanabe K and Okuno T and Ogura M and Yoshida K and Takeuchi M and Nakajima T,https://pubmed.ncbi.nlm.nih.gov/24366758/,24366758,No local,No local
1024,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 3,NCT00920816,No name,Renal cell cancer,Industry,Pfizer Inc,2,1,Axitinib,Target therapy,Sorafenib,Target therapy,PFS,RECIST 1.0,192,96,NA,NA,NA,NA,0.77,0.56,1.05,NA,NA,NA,NA,192,62,96,14,NR,NR,NR,NR,NR,Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.,The Lancet. Oncology,2013,Hutson TE and Lesovoy V and Al-Shukri S and Stus VP and Lipatov ON and Bair AH and Rosbrook B and Chen C and Kim S and Vogelzang NJ,https://pubmed.ncbi.nlm.nih.gov/24206640/,24206640,No local,No local
1058,Investigator + Central,Investigator,Investigator + Central,Investigator,Blinding,Phase 3,NCT00637910,TAILOR,Non-small cell lung cancer,Industry,Agenzia Italiana del Farmaco,2,2,Erlotinib,Chemotherapy,docetaxel,Target therapy,OS,RECIST 1.1,112,110,33,0.71,0.53,0.95,NA,NA,NA,100,3,97,15,NA,NA,NA,NA,8.2,5.4,0.73,0.53,1,Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.,The Lancet. Oncology,2013,Garassino MC and Martelli O and Broggini M and Farina G and Veronese S and Rulli E and Bianchi F and Bettini A and Longo F and Moscetti L and Tomirotti M and Marabese M and Ganzinelli M and Lauricella C and Labianca R and Floriani I and Giaccone G and Torri V and Scanni A and Marsoni S,https://pubmed.ncbi.nlm.nih.gov/23883922/,23883922,No central,No central
1079,Investigator + Central,Investigator?,Investigator + Central,Investigator?,Unclear,Phase 3,ISRCTN93248876,PICCOLO,Colorectal cancer,Industry and Public,"Cancer Research UK, Amgen Inc.",2,≥2,Panitumumab and irinotecan,Target therapy and Chemotherapy,irinotecan,Chemotherapy,OS,RECIST 1.0,230,230,NA,0.78,0.64,0.95,NA,NA,NA,230,79,230,27,NA,NA,NA,NA,10.4,10.9,1.01,0.83,1.23,"Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.",The Lancet. Oncology,2013,Seymour MT and Brown SR and Middleton G and Maughan T and Richman S and Gwyther S and Lowe C and Seligmann JF and Wadsley J and Maisey N and Chau I and Hill M and Dawson L and Falk S and O'Callaghan A and Benstead K and Chambers P and Oliver A and Marshall H and Napp V and Quirke P,https://pubmed.ncbi.nlm.nih.gov/23725851/,23725851,No central,No central
1169,Investigator + Central,Investigator?,Investigator + Central,Investigator?,Blinding,Phase 2,NA,No name,Non-small cell lung cancer,Public,National Cancer Center,4,1,irinotecan plus cisplatin,Chemotherapy,irinotecan plus capecitabine,Chemotherapy,ORR,RECIST 1.0,37,37,14.5,1.71,1.05,2.78,NA,NA,NA,,49%,,30%,NA,NA,NA,NA,14.5,16.1,0.62,0.39,1,A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer.,Annals of oncology : official journal of the European Society for Medical Oncology,2012,Han JY and Nam BH and Kim HY and Yoon SJ and Kim HT and Lee JS,https://pubmed.ncbi.nlm.nih.gov/22782331/,22782331,No central,No ORR
1186,No PFS,TTP,Investigator + Central,Investigator?,Blinding,Phase 2,NA,TBCRC 001,Breast cancer,Industry,Bristol-Myers,2,≥1,cetuximab + carboplatin,Target therapy and Chemotherapy,cetuximab,Target therapy,ORR,RECIST 1.0? 1.1?,71,31,26,NA,NA,NA,NA,NA,NA,71,12,31,2,NA,NA,NA,NA,10.4,7.5,NA,NA,NA,TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2012,Carey LA and Rugo HS and Marcom PK and Mayer EL and Esteva FJ and Ma CX and Liu MC and Storniolo AM and Rimawi MF and Forero-Torres A and Wolff AC and Hobday TJ and Ivanova A and Chiu WK and Ferraro M and Burrows E and Bernard PS and Hoadley KA and Perou CM and Winer EP,https://pubmed.ncbi.nlm.nih.gov/22665533/,22665533,No PFS,No central
1192,No PFS,TTP,Investigator + Central,CBR,Unclear,Phase 2,NA,No name,Breast cancer,Industry,Novartis Pharmaceuticals,2,≥1,Tamoxifen and Everolimus,Target therapy and Chemotherapy,Everolimus,Chemotherapy,clinical benefit rate,RECIST 1.0,54,57,23.7/24.2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,54,5,57,5,NR,32.9,0.45,0.24,0.81,"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2012,Bachelot T and Bourgier C and Cropet C and Ray-Coquard I and Ferrero JM and Freyer G and Abadie-Lacourtoisie S and Eymard JC and Debled M and Spaﾃｫth D and Legouffe E and Allouache D and El Kouri C and Pujade-Lauraine E,https://pubmed.ncbi.nlm.nih.gov/22565002/,22565002,No PFS,No local
1211,No PFS,TTP,Investigator + Central,Central,Unclear,Phase 2,NCT00419042,GFPC 0505,Non-small cell lung cancer,Industry,"Roche, Lilly, Sanofi-Aventis and Chugai",2,1,gemcitabine followed by erlotinib,Target therapy and Chemotherapy,erlotinib followed by gemcitabine,Target therapy and Chemotherapy,TTP2,RECIST 1.0,44,50,NA,NA,NA,NA,NA,NA,NA,data not shown,,,,38,5,43,6,NA,NA,NA,NA,NA,"A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).","Lung cancer (Amsterdam, Netherlands)",2012,LeCaer H and Greillier L and Corre R and Jullian H and Crequit J and Falchero L and Dujon C and Berard H and Vergnenegre A and Chouaid C,https://pubmed.ncbi.nlm.nih.gov/22405570/,22405570,No PFS,No local
1217,Investigator + Central,Investigator?,Investigator + Central,Investigator?,Blinding,Phase 3,NA,First-SIGNAL,Non-small cell lung cancer,Industry and Public,National Cancer Center and AstraZeneca,2,1,Gefitinib,Target therapy,Gemcitabine and Cisplatin,Chemotherapy,OS,WHO criteria,159,154,35,1.198,0.944,1.52,NA,NA,NA,159,88,150,69,NA,NA,NA,NA,22.3,22.9,0.932,0.716,1.213,First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.,Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2012,Han JY and Park K and Kim SW and Lee DH and Kim HY and Kim HT and Ahn MJ and Yun T and Ahn JS and Suh C and Lee JS and Yoon SJ and Han JH and Lee JW and Jo SJ and Lee JS,https://pubmed.ncbi.nlm.nih.gov/22370314/,22370314,No central,No central
1225,Investigator + Central,Investigator?,Investigator + Central,Investigator?,Unclear,Phase 3,NCT00446225,EURTAC,Non-small cell lung cancer,Industry and Public,"Spanish Lung Cancer Group, Roche Farma, Hoff mann-La Roche, and Red Temática de Investigacion
Cooperativa en Cancer.",2,1,Erlotinib,Target therapy,Chemotherapy,Chemotherapy,PFS,RECIST 1.0,86,87,18.9/14.4,0.37,0.25,0.54,NA,NA,NA,86,50,87,13,NA,NA,NA,NA,19.3,19.5,1.04,0.65,1.68,"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",The Lancet. Oncology,2012,Rosell R and Carcereny E and Gervais R and Vergnenegre A and Massuti B and Felip E and Palmero R and Garcia-Gomez R and Pallares C and Sanchez JM and Porta R and Cobo M and Garrido P and Longo F and Moran T and Insa A and De Marinis F and Corre R and Bover I and Illiano A and Dansin E and de Castro J and Milella M and Reguart N and Altavilla G and Jimenez U and Provencio M and Moreno MA and Terrasa J and Muﾃｱoz-Langa J and Valdivia J and Isla D and Domine M and Molinier O and Mazieres J and Baize N and Garcia-Campelo R and Robinet G and Rodriguez-Abreu D and Lopez-Vivanco G and Gebbia V and Ferrera-Delgado L and Bombaron P and Bernabe R and Bearz A and Artal A and Cortesi E and Rolfo C and Sanchez-Ronco M and Drozdowskyj A and Queralt C and de Aguirre I and Ramirez JL and Sanchez JJ and Molina MA and Taron M and Paz-Ares L,https://pubmed.ncbi.nlm.nih.gov/22285168/,22285168,No central,No central
1238,Investigator + Central,Investigator,Investigator + Central,Investigator?,Unclear,Phase 2,NCT00628251,No name,Ovarian cancer,Industry and Public,"AstraZeneca. S.B.K. Cancer Research UK and the Department of Health, through Experimental Cancer Medicine Centre and Biomedical Research Centre grants to the Royal Marsden Hospital and Institute of Cancer Research.",3,≥2,olaparib 200mg,Target therapy,pegylated liposomal doxorubicin,Chemotherapy,PFS,RECIST 1.0,32,33,NA,0.91,0.48,1.74,Data not shown,,,32,8,33,6,NA,NA,NA,NA,NA,NA,0.66,0.27,1.55,"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2012,Kaye SB and Lubinski J and Matulonis U and Ang JE and Gourley C and Karlan BY and Amnon A and Bell-McGuinn KM and Chen LM and Friedlander M and Safra T and Vergote I and Wickens M and Lowe ES and Carmichael J and Kaufman B,https://pubmed.ncbi.nlm.nih.gov/22203755/,22203755,No central,No central
1251,Investigator + Central,Investigator,Investigator + Central,Investigator,Unclear,Phase 2,NCT00338130,No name,Melanoma,Industry,AstraZeneca,2,1,Selumetinib,Target therapy,Temozolomide,Chemotherapy,PFS,RECIST 1.0,104,96,NA,1.07,0.86,1.32,NA,NA,NA,104,6,96,9,NA,NA,NA,NA,284 days,369 days,1.351,0.95,1.93,"Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",Clinical cancer research : an official journal of the American Association for           Cancer Research,2012,Kirkwood JM and Bastholt L and Robert C and Sosman J and Larkin J and Hersey P and Middleton M and Cantarini M and Zazulina V and Kemsley K and Dummer R,https://pubmed.ncbi.nlm.nih.gov/22048237/,22048237,No central,No central
1264,Investigator + Central,TTP,Investigator + Central,Central,Unclear,Phase 2,NCT00418704,GFPC 0504,Non-small cell lung cancer,Industry,"Roche, Lilly, Sanofi-Aventis and Chugai",2,1,docetaxel/gemcitabine followed by erlotinib,Target therapy and Chemotherapy,erlotinib followed by docetaxel/gemcitabine,Target therapy and Chemotherapy,TTP2,RECIST 1.0,48,51,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,48,10,51,9,9.4,7.1,NA,NA,NA,"A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).",British journal of cancer,2011,LeCaer H and Barlesi F and Corre R and Jullian H and Bota S and Falchero L and Vergnenegre A and Dujon C and Delhoume JY and Chouaid C,https://pubmed.ncbi.nlm.nih.gov/21934690/,21934690,No PFS,No local
1308,Central,Investigator,Investigator + Central,Investigator,Unclear,Phase 2/3,NCT00112658,No name,Pancretic cancer,Public,French government,2,1,FOLFIRINOX,Chemotherapy,Gemcitabine,Chemotherapy,OS,RECIST 1.0,171,171,26.6,0.47,0.37,0.59,NA,NA,NA,171,54,171,16,NA,NA,NA,NA,11.1,6.8,0.57,0.45,0.73,FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.,The New England journal of medicine,2011,Conroy T and Desseigne F and Ychou M and Bouchﾃｩ O and Guimbaud R and Bﾃｩcouarn Y and Adenis A and Raoul JL and Gourgou-Bourgade S and de la Fouchardiﾃｨre C and Bennouna J and Bachet JB and Khemissa-Akouz F and Pﾃｩrﾃｩ-Vergﾃｩ D and Delbaldo C and Assenat E and Chauffert B and Michel P and Montoto-Grillot C and Ducreux M,https://pubmed.ncbi.nlm.nih.gov/21561347/,21561347,No central,No central
1366,Central,Central,Investigator + Central,Central,Blinding,Phase 2,NA,No name,Non-small cell lung cancer,Industry,Merck KGaA,3,2,Pemetrexed Plus Matuzumab (800 mg/wk),Target therapy and Chemotherapy,Pemetrexed,Chemotherapy,ORR,WHO criteria,51,50,NA,Data not shown,,,0.96,0.59,1.56,Data not shown,,,,51,8,50,2,12.4,7.9,0.67,0.37,1.21,Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.,Journal of thoracic oncology : official publication of the International Association           for the Study of Lung Cancer,2010,Schiller JH and von Pawel J and Schﾃｼtt P and Ansari RH and Thomas M and Saleh M and McCroskey RD and Pfeifer W and Marsland TA and Kloecker GH and Sebastian M and Pirker R and Kurek R and Beadman C and Socinski MA,https://pubmed.ncbi.nlm.nih.gov/20978446/,20978446,No local,No local
1374,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 3,NCT00339183,20050181,Colorectal cancer,Industry,Amgen Inc,2,2,Panitumumab and FOLFIRI,Target therapy and Chemotherapy,FOLFIRI,Chemotherapy,OS and PFS,RECIST 1.0,303,294,10.2/13.3,NA,NA,NA,0.73,0.59,0.9,NA,NA,NA,NA,297,104,285,29,14.5,12.5,0.85,0.7,1.04,"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2010,Peeters M and Price TJ and Cervantes A and Sobrero AF and Ducreux M and Hotko Y and Andrﾃｩ T and Chan E and Lordick F and Punt CJ and Strickland AH and Wilson G and Ciuleanu TE and Roman L and Van Cutsem E and Tzekova V and Collins S and Oliner KS and Rong A and Gansert J,https://pubmed.ncbi.nlm.nih.gov/20921462/,20921462,No local,No local
1380,Investigator + Central,"Central, No HR",Investigator + Central,Central,Blinding,Phase 2,NA,No name,Gastric cancer,Unclear,,2,1,Docetaxel/cisplatin followed by FOLFIRI,Chemotherapy,FOLFIRI followed by Docetaxel/cisplatin,Chemotherapy,Unclear,RECIST 1.0,28,30,38.2,NA,NA,NA,No HR,No HR,No HR,NA,NA,NA,NA,28,7,30,14,12.5,13.4,No HR,No HR,No HR,Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.,Cancer chemotherapy and pharmacology,2011,Kim JA and Lee J and Han B and Park SH and Park JO and Park YS and Lim HY and Kang WK,https://pubmed.ncbi.nlm.nih.gov/20878159/,20878159,No PFS,No local
1383,Investigator + Central,Central,No ORR,No ORR,Blinding,Phase 3,CRUK/01/010,NA,Glioma,Public,Cancer Research United Kingdom,2,1,Temozolomide,Chemotherapy,"Procarbazine, Lomustine and Vincristine",Chemotherapy,OS and PFS,Unclear,224,223,12,NA,NA,NA,0.89,0.73,1.08,NA,NA,NA,NA,NA,NA,NA,NA,6.7,7.2,0.91,0.74,1.11,"Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.",Journal of clinical oncology : official journal of the American Society of Clinical           Oncology,2010,Brada M and Stenning S and Gabe R and Thompson LC and Levy D and Rampling R and Erridge S and Saran F and Gattamaneni R and Hopkins K and Beall S and Collins VP and Lee SM,https://pubmed.ncbi.nlm.nih.gov/20855843/,20855843,No local,No ORR
1432,Investigator + Central,Central,Investigator + Central,Central,Blinding,Phase 2,NCT0021564436,No name,oesophago-gastric cancer,Industry,Merck KGaA,2,1,"Matuzumab plus epirubicin, cisplatin and capecitabine",Target therapy and Chemotherapy,"epirubicin, cisplatin and capecitabine",Chemotherapy,ORR,WHO criteria,36,36,28.5/23.0,NA,NA,NA,1.13,0.63,2.01,NA,NA,NA,NA,35,11,36,21,9.4,12.2,1.02,0.61,1.7,"Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.",Annals of oncology : official journal of the European Society for Medical Oncology,2010,Rao S and Starling N and Cunningham D and Sumpter K and Gilligan D and Ruhstaller T and Valladares-Ayerbes M and Wilke H and Archer C and Kurek R and Beadman C and Oates J,https://pubmed.ncbi.nlm.nih.gov/20497967/,20497967,No local,No local
1438,Investigator + Central,TTP,Investigator + Central,Central,Blinding,Phase 2,NA,No name,Prostate cancer,Industry,Antisoma Research Limited,2,1,Vadimezan and Docetaxel,Target therapy and Chemotherapy,Docetaxel,Chemotherapy,Unclear,RECIST 1.0,35,39,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,33,8,38,3,17,17.2,0.8,0.46,1.39,"Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.",Clinical cancer research : an official journal of the American Association for           Cancer Research,2010,Pili R and Rosenthal MA and Mainwaring PN and Van Hazel G and Srinivas S and Dreicer R and Goel S and Leach J and Wong S and Clingan P,https://pubmed.ncbi.nlm.nih.gov/20460477/,20460477,No PFS,No local
1496,No PFS,No PFS,Investigator + Central,No ORR,Unclear,Phase 2,NA,No name,Breast cancer,Industry,Merck Serono,2,≥2,High-dose adecatumumab,Target therapy,Low-dose adecatumumab,Target therapy,clinical benefit rate (CBR),RECIST 1.0? ,NA,NA,NA,NA,NA,NA,NA,NA,NA,No ORR,No ORR,No ORR,No ORR,No ORR,No ORR,No ORR,No ORR,NA,NA,NA,NA,NA,"An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.",Annals of oncology : official journal of the European Society for Medical Oncology,2010,Schmidt M and Scheulen ME and Dittrich C and Obrist P and Marschner N and Dirix L and Schmidt M and Rﾃｼttinger D and Schuler M and Reinhardt C and Awada A,https://pubmed.ncbi.nlm.nih.gov/19633042/,19633042,No PFS,No ORR
1513,Investigator + Central,Investigator,Investigator + Central,Investigator,Unclear,Phase 3,NCT01287624,CBCSG006,Brest cancer,Public,Shanghai Natural Science Foundation,2,1,Cisplatin plus gemcitabine,Chemotherapy,paclitaxel plus gemcitabine,Chemotherapy,PFS,RECIST 1.1,120,120,16.3/15.9,0.692,0.523,0.915,NA,NA,NA,118,76,118,58,NA,NA,NA,NA,NA,NA,0.902,0.605,1.344,"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial",The Lancet. Oncology,2015,"Xi-Chun Hu 1, Jian Zhang 2, Bing-He Xu 3, Li Cai 4, Joseph Ragaz 5, Zhong-Hua Wang 2, Bi-Yun Wang 2, Yue-E Teng 6, Zhong-Sheng Tong 7, Yue-Yin Pan 8, Yong-Mei Yin 9, Chang-Ping Wu 10, Ze-Fei Jiang 11, Xiao-Jia Wang 12, Gu-Yin Lou 13, Dong-Geng Liu 14, Ji-Feng Feng 15, Jian-Feng Luo 16, Kang Sun 17, Ya-Jia Gu 18, Jiong Wu 19, Zhi-Min Shao 19",https://pubmed.ncbi.nlm.nih.gov/25795409/,25795409,No central,No central